West Pharmaceutical Services, Inc. (WST) Earnings Call Transcripts

West Pharmaceutical Services, Inc.'s Latest Earnings Call - Q2 FY2026

In Q2 2026, West Pharmaceutical Services reported revenues of $872 million, reflecting a 13% organic growth, and adjusted EPS of $2.37, up 29% year-over-year. The strong performance surpassed market expectations, prompting management to raise full-year guidance for organic revenue growth to 10-11% and adjusted EPS to a range of $8.85 to $9.05. The results were driven by robust growth in the Proprietary Products segment, particularly in HVP components and GLP-1 therapies, despite some impacts from a recent cyber incident.

Reported metrics

Guidance from management

Management raised full-year revenue guidance to $3.345-$3.38 billion, reflecting an organic growth expectation of 10-11%. Adjusted EPS guidance was also increased to $8.85-$9.05, indicating confidence in ongoing business momentum.

What management said

Yes. Yes. I think we feel very good about the ongoing momentum. As I mentioned in our prepared remarks, we're taking kind of one quarter at a time and kind of a prudent approach. But don't read too much into it. We feel very good about the underlying momentum, particularly in the HVP components business that really drives not only the top line, but our profit. We feel like we're well placed to continue to drive a ver...

And David, just to add on to what Eric is saying and if we think about kind of the long-term opportunity for Annex 1, we're actually seeing some of the lower-end HVP products also being upgraded. And so while the big piece is actually moving from standard to the HVP or core to HVP, we're also seeing additional steps being asked for by our customers. to take an existing HVP product and even adding more value to it. An...

What analysts pressed on

Analysts expressed concerns regarding the impact of the cyber incident on West Vantage's performance and the perceived conservatism in guidance despite strong Q2 results. There were questions about the sustainability of growth in non-GLP-1 HVP components and the potential for future margin expansion.

Main topics on the call

• Revenue Growth Acceleration — West reported Q2 revenues of $872 million, up 13% organically. Management noted, "Our performance was driven by the execution of our strategy and continued operational excellence initiatives," indicating strong momentum.
• Guidance Increase — Management raised full-year guidance for organic revenue growth to 10-11% from a previous range of 7-9%. Adjusted EPS guidance was also increased to $8.85-$9.05, reflecting confidence in ongoing business momentum.
• HVP Components Growth — The HVP components business grew 18.4% organically, driven by strong demand in biologics and GLP-1 therapies. Eric Green stated, "We continue to have strong win rates of over 90% for these new molecules," highlighting th...
• Impact of Cyber Incident — The West Vantage segment grew only 0.8% organically, slightly below expectations due to the cyber incident's impact. Bob McMahon noted, "We estimate this was a mid-single-digit impact to growth in the quarter," indicatin...

Read the full West Pharmaceutical Services, Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 77 West Pharmaceutical Services, Inc. earnings call transcripts on record, spanning January 16, 2020 to July 23, 2026. Based on this history, West Pharmaceutical Services, Inc. reports quarterly. The most recent call on file is dated July 23, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

WST

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

77

First call

January 16, 2020

Most recent

July 23, 2026

Reporting cadence

quarterly